Advicenne Announces the Appointment of André Ulmann as Interim Chief Executive Officer
March 13, 2020
Nîmes, France, March 13, 2020 (7:45 a.m. CET) – Advicenne (Euronext Paris & Brussels: ADVIC – FR0013296746), a specialty pharmaceutical company focused on the development and commercialization of therapeutic products for orphan renal and neurological diseases, today announces that Dr Luc-André Granier has left his role as CEO of the Company. The Board of Directors has elected Dr. André Ulmann, current Board Observer of the company, as Interim CEO of Advicenne, with immediate effect.